School of Health and Social Care Dean's Lecture: Professor Stanton Newman

Over 3 million people in the UK have Chronic Kidney Disease, a significant number of whom will go on to develop End Stage Renal Disease (ESRD aka End Stage Kidney Disease - ESKD). Dubbed ‘the silent killer’ kidney disease often has no symptoms and up to one million have not been diagnosed and are unaware they have the condition.

It is known that 60,000 people each year die prematurely from the effects of chronic kidney disease, with 64,000 being treated for end stage renal failure with kidney dialysis or a kidney transplant annually. According to the UK Renal Registry, the number of people with end stage kidney failure is increasing by 4% every year.

The talk will cover the research that Professor Newman has been doing with colleagues to identify the issues of those in receipt of treatment for ESRD. It will cover the impact of different forms of dialysis and transplantation. It will then present the work they have been doing to assist people in self managing their renal condition so as to improve their quality of life and reduce the deleterious effects and complications of the condition and its treatments.

16:00-17:00 - Dean's Lecture by Professor Stanton Newman

17:00-18:00 - Reception

How to attend

Register via Eventbrite to hear Professor Stanton give the School of Health and Social Care Dean's Lecture, on End Stage Renal Disease.

This seminar is being held in person in the STEM event space. You can also watch via Zoom (meeting ID: 999 2531 8102)

About Professor Stanton Newman

Prof Stanton Newman is a Chartered Health and Clinical Psychologist, A Fellow of British Psychological Society, Honorary Fellow of the Royal College of Physicians and Previous Chair of the Division of Health Psychology of the BPS.

He has held positions at the London School of Economics and Guys Hospital Medical School. He them moved to Middlesex Hospital Medical School where he taught Medical Students. In 1992 he was appointed as a Professor of Health Psychology and in 1993 he was appointed Head of Psychiatry and Behavioural Science at UCL Medical School where he grew the department to 33 full time academic staff. The Department achieved top research rating in the Research Assessment Exercise. In 2004 he established a new Centre of Behavioural and Social Science in Medicine in the Division of Medicine at UCL where the first Masters in Health Psychology was run jointly with other Colleges.

Whilst at UCL he ran a clinic at UCL Hospitals where he had referrals from a range of medical and surgical departments.

In 2010 he was appointed Dean of Health Sciences at City, University of London. After improving the financial health of the School he increased the schools teaching and research performance and secured a new building to house all the staff. The school was ranked 9th in the Unit of assessment in the UK on Research Power of the Ref. In 2014 he was appointed Vice president (International) at City. In this role he established an office of Global Engagement, organised delegations to visit to targeted countries abroad, increased both staff and student mobility from the University and expanded transnational Education. In 2020 Prof Newman stepped down from his administrative roles to increase his focus on research. To date he has published over 280 journal articles, 60 Chapters and written or edited over 15 books. Over his career he has been involved in research grants totalling over £20m. Most recently in 2023 he was awarded an NIHR Programme grants of £2.7m for a programme of research to reduce cardiovascular disease in people with serious mental illness (Pegasus Study).

One focus of his research is on the impact on the brain of various forms of surgery and treatments. His group identified cognitive impairment following routine cardiac surgery, identified the principal causes and went on to identify techniques and equipment to reduce these impairments. This work was the subject of a BBC documentary.

He has also pioneered work on self-management of a range of chronic conditions including renal disease, heart failure, arthritis, ocular conditions, coronary artery disease and diabetes. A further focus of his research is on the role and integration of technology into the management of chronic disease.

He has served on a number of Grant Awarding Bodies. He has also been involved in helping to spin out companies from the University and has served as Non Executive Director/Governor in companies and charities.